Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma.
Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma.
复制标题
DOI：
10.1016/j.nano.2016.10.015
复制
发表时间：
2017-02
影响因子：
5.4
通讯作者：
Fernandes, Rohan
中科院分区：
文献类型：
--
作者：
Cano-Mejia, Juliana;Burga, Rachel A.;Sweeney, Elizabeth E.;Fisher, John P.;Bollard, Catherine M.;Sandler, Anthony D.;Cruz, Conrad Russell Y.;Fernandes, Rohan
关键词：
我们描述了“光热免疫疗法”，它将基于普鲁士蓝纳米颗粒（PBNP）的光热疗法（PTT）与抗CTLA-4检查点抑制相结合，用于治疗神经母细胞瘤，这是一种常见的难以治疗的儿科癌症。PBNP表现出pH依赖性稳定性，这使得它们适合于肿瘤内施用的PTT。基于PBNP的PTT能够降低肿瘤负荷并引发免疫应答，特别是淋巴细胞和T细胞向肿瘤区域的浸润增加，这通过抗CTLA-4免疫疗法的抗肿瘤作用来补充，从而在动物模型中提供针对神经母细胞瘤的更持久的治疗。我们观察到光热免疫疗法处理的小鼠在100天时的存活率为55.5%，相比之下，接受单独的抗CTLA-4、单独的PBNP、单独的PTT和未处理的小鼠的存活率分别为12.5%、0%、0%和0%。此外，长期存活的光热免疫治疗小鼠表现出对神经母细胞瘤再激发的保护作用，表明对这些肿瘤的免疫力的发展。我们的研究结果表明光热免疫疗法在改善神经母细胞瘤治疗方面的潜力。
We describe “photothermal immunotherapy,” which combines Prussian blue nanoparticle (PBNP)-based photothermal therapy (PTT) with anti-CTLA-4 checkpoint inhibition for treating neuroblastoma, a common, hard-to-treat pediatric cancer. PBNPs exhibit pH-dependent stability, which makes them suitable for intratumorally-administered PTT. PBNP-based PTT is able to lower tumor burden and prime an immune response, specifically an increased infiltration of lymphocytes and T cells to the tumor area, which is complemented by the antitumor effects of anti-CTLA-4 immunotherapy, providing a more durable treatment against neuroblastoma in an animal model. We observe 55.5% survival in photothermal immunotherapy-treated mice at 100 days compared to 12.5%, 0%, 0%, and 0% survival in mice receiving: anti-CTLA-4 alone, PBNPs alone, PTT alone, and no treatment, respectively. Additionally, long-term surviving, photothermal immunotherapy-treated mice exhibit protection against neuroblastoma rechallenge, suggesting the development of immunity against these tumors. Our findings suggest the potential of photothermal immunotherapy in improving treatments for neuroblastoma.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
影响因子：
14
作者：
Burke, Andrew R.;Singh, Ravi N.;Carroll, David L.;Wood, James C. S.;D'Agostino, Ralph B., Jr.;Ajayan, Pulickel M.;Torti, Frank M.;Torti, Suzy V.
通讯作者：
Torti, Suzy V.
DOI：
10.1073/pnas.2232479100
发表时间：
2003-11-11
影响因子：
11.1
作者：
Hirsch, LR;Stafford, RJ;West, JL
通讯作者：
West, JL
影响因子：
11.5
作者：
Hodi, F. Stephen
通讯作者：
Hodi, F. Stephen
影响因子：
3.7
作者：
Bear AS;Kennedy LC;Young JK;Perna SK;Mattos Almeida JP;Lin AY;Eckels PC;Drezek RA;Foster AE
通讯作者：
Foster AE